Feature articles
Research in care homes is pushing new boundaries (PDF 215kb)
It’s no secret that better lifestyles and improved healthcare is leading to us living for longer. So it’s also no surprise that more people in the later stages of life are also suffering with various forms of dementia. In less than 10 years the number of people living with dementia will be more than one million, which according to 2012 fi gures by the Alzheimer’s Society, currently costs the UK £23 billion a year.
Embracing patient and public involvement (PDF, 33kb)
The Dementias and Neurodegenerative Diseases Research Network (DeNDRoN) has introduced innovative training sessions on how to best to assess mental capacity and gain informed consent from potential study participants.
The whole Network approach (PDF, 104kb)
Alzheimer’s disease is the most common cause of dementia and affects around 750,000 people in the UK. The Alzheimer’s Society estimates the financial cost to the UK to be over £20 billion a year. A recent commercial study supported by the Dementias and Neurodegenerative Diseases Research Network (DeNDRoN) is looking at a new tool which could help to plan for future dementia treatments and services.
Network support helps new relationships blossom (PDF, 144kb)
The Clinical Research Network is expanding, with the number of research sites in the NHS continuing to grow. This is positive news for society, with more patients getting the opportunity to access leading-edge techniques and treatments, and it’s also of huge benefit to the Life-science Industry. With a broader range of locations to recruit from, Industry can reduce its reliance on established partners and use the Network’s match-making skills to couple them with new sites that can set-up on time and recruit the patients they need.
Helping shape Government dementia research strategy (PDF, 193kb)
An ageing population is placing ever greater pressure on the NHS. This is changing the demographic profile of many diseases, but perhaps the impact is most starkly felt in dementia care. In 2010 the Alzheimer’s Research Trust estimated that dementia cost the UK £23 billion a year. It costs twice as much as cancer, three times as much as heart disease and four times as much as stroke – but dementia research receives substantially less funding than these conditions and functions within a fragmented care environment.
Change of gear for Motor Neurone Disease research (PDF, 452kb)
In 2007 two events took place which helped change the course of Motor Neurone Disease (MND) clinical research in England. The Dementias and Neurodegenerative Diseases Research Network (DeNDRoN) became operational and the Motor Neurone Disease (MND) Association took a conscious decision to become more involved in clinical and healthcare research. Three years on, the number of MND studies on the Clinical Research Network Portfolio has risen from one to 23, and exciting results are providing a focus for researchers and encouragement to the wider MND community.
Networking for success (PDF, 156kb)
By drawing on established, new and cross-Network relationships, DeNDRoN achieved its highest recruitment for a commercial study to date and suitably impressed a commercial sponsor to boot.
All for one, one for all (PDF, 229kb)
It’s important for the UK economy that we successfully deliver research studies for the life-sciences industry. The Dementias and Neurodegenerative Diseases Research Network (DeNDRoN) are doing just that; as the CONFIDENT study demonstrates.
